Lisa Astor | Authors


Phase 2 Trial Suggests Trilaciclib Before Chemo Significantly Improves OS in Metastatic TNBC

December 10, 2020

Final data from a phase 2 trial suggested that the administration of trilaciclib before chemotherapy comprised of gemcitabine and carboplatin resulted in a significant improvement in overall survival in previously treated patients with metastatic triple-negative breast cancer.

Reviewing Various Biomarker Settings for Patients with Prostate Cancer

December 04, 2020

The last 5 years in prostate cancer have seen exponential growth for the field of biomarkers. Specifically, not only do guidelines that now incorporate many biomarkers offer guidance on how to treat these patients, but they can also assess the potential for developing prostate cancer.

Frontline Fulvestrant, Palbociclib Combo Effective for Endocrine-Sensitive, HR+/HER2- Metastatic Breast Cancer

September 21, 2020

Findings from the phase 2 FLIPPER trial indicated that frontline fulvestrant (Faslodex) in combination with palbociclib (Ibrance) demonstrated an improvement in PFS at 1 year in patients with endocrine-sensitive HR-positive, HER2-negative metastatic breast cancer.